agenT-797
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Distress Syndrome, Adult
Conditions
Respiratory Distress Syndrome, Adult
Trial Timeline
Sep 21, 2020 → Apr 23, 2023
NCT ID
NCT04582201About agenT-797
agenT-797 is a phase 1 stage product being developed by MiNK Therapeutics for Respiratory Distress Syndrome, Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT04582201. Target conditions include Respiratory Distress Syndrome, Adult.
What happened to similar drugs?
4 of 20 similar drugs in Respiratory Distress Syndrome, Adult were approved
Approved (4) Terminated (1) Active (15)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04754100 | Phase 1 | Completed |
| NCT04582201 | Phase 1 | Completed |
Competing Products
20 competing products in Respiratory Distress Syndrome, Adult
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Preclinical | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 44 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 30 |
| YMC026 + Placebo | Yuhan | Approved | 43 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 35 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 32 |
| S-337395 + Placebo | Shionogi | Phase 2 | 42 |
| Sivelestat | Eli Lilly | Phase 1/2 | 32 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 35 |